Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia

Leukemia

Volumn 11, Issue 10, 1997, Pages 1617-1620

  Kantarjian, H M ^a   O'Brien, S M ^a   Keating, M ^a   Beran, M ^a   Estey, E ^a   Giralt, S ^a   Kornblau, S ^a   Rios, M B ^a   De Vos, D ^b   Talpaz, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEVA Pharmachemie   (Netherlands)

Author keywords

Decitabine in CML; Methylation in CML

Indexed keywords

5 AZA 2' DEOXYCYTIDINE;

ADULT; ARTICLE; BLAST CELL CRISIS; BONE MARROW; BONE MARROW SUPPRESSION; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DIARRHEA; FEVER; GRANULOCYTE; HUMAN; INFECTION; LEUKOCYTE COUNT; MUCOSA INFLAMMATION; NAUSEA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; THROMBOCYTE COUNT; VOMITING;

EID: 16944363756     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400796     Document Type: Article

References (21)

1. Pinto A, Zagonel V. 5-Aza-2′-deoxycytidine (decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 1993; 7 (Suppl. 1): 51-60.
2. Issa J-P, Baylin SC, Herman JG. DNA methylation changes in hematologic malignancies: biologic and clinical implications, Leukemia 1997; 11 (Suppl. 1): 7-11.
3. Petti MC, Mandelli F, Zagonel V et al. Pilot study of 5-aza-2′-deoxycytidine (decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 1993; 7: 36-41.
4. Willemze R, Archimbaud E, Muus P. Preliminary results with 5-aza-2′-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. Leukemia 1993; 7: 49-50.
5. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 1997; 11: 1-5.
6. Kantarjian HM, Deisseroth A, Kurzrock R, Estrov Z, Talpaz M. Chronic myelogenous leukemia: a concise update. Blood 1993; 82: 691-703.
7. Kantarjian HM, Keating MJ, Talpaz M et al. Chronic myelogenous leukemia in blastic crisis: analysis of 242 patients. Am J Med 1987; 83: 445-454.
8. Kantarjian HM, Talpaz M, Kontoyiannis D, Gutterman J, Keating MJ, Estey EH, O'Brien S, Rios M-B, Beran M, Deisseroth A. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocytemacrophage colony-stimulating factor. J Clin Oncol 1992; 10: 398-405.
9. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988; 61: 1441-1446.
10. Kantarjian HM, Beran M, Ellis A et al. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 1993; 81: 1146-1151.
11. Momparler RL, Gyger M, Rivard CE. Clinical trial on 5-aza-2′-deoxycytidine in patients with acute leukemia. Pharmacol Ther 1985; 30: 277-286.
12. Zion M, Ben-Yehuda D, Auraham A, Cohen O, Wetzler M, Melloul D, Ben-Neriah Y. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Pmc Natl Acad Sci USA 1994; 91: 10722-10726.
13. Ben-Yehuda D, Krichevsky S, Rachmilewitz EA, Palumbo GA, Frassoni F, Saar D, Ben-Neriah Y. Monitoring disease progression and Interferon therapy in CML by abl promoter methylation. Blood 1996; 88 (Suppl. 1): 637a.
14. Herman JG, Latiff F, Weng F, Weng Y, Lerman M, Zbar B, Liu S, Samid D, Duan DSR, Gnarra JR, Linehan WM, Baylin SB. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91: 9700-9704.
15. Otterson GA, Khleif SN, Chen W, Coxon A, Kaye FJ. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16 protein induction by 5-aza-2′-deoxycytidine. Oncogene 1995; 11: 1211-1216.
16. Kornblau SM, Xu H, Zhang W, Hu S, Beran M, Smith T, Hester J, Estey E, Benedict W, Deisseroth A. Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood 1994; 84: 256-261.
17. Giralt S, Davis M, O'Brien S, van Besien K, Champlin R, de Vos D, Kantarjian HM. Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia 1997; 11 (Suppl. 1): 32-34.
18. Anzai H, Frost P, Abbrussese JL. Synergistic cytoxicity with 2′-deoxy-5-azacytidine and topotecan in vitro and in vivo. Cancer Res 1992; 52: 2180-2185.
19. Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng Y-C, Gorchow LB, Kaufman SH. Phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 1994; 12: 2193-2203.
20. Beran M, Kantarjian H, O'Brien S et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996; 88: 2473-2479.
21. List AF, Heaton R, Glinsmann-Gibson B, Brasfield F, Crook L, Chartrand C, Taetle R, Kurman M. Amifostine promotes multilineage hematopoiesis in patients with myelodysplastic syndrome: results of a phase I/II clinical trial. Blood 1996; 88 (Suppl. 1): 453a.